Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
NEW YORK, April 19, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020http://www.reportlinker.com/p0843058/Ovarian-Cancer-Therapeutics---Global-Drug-Forecasts-and-Treatment-Analysis-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
Summary EuropeThis report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
The ovarian cancer therapeutics market grew at a Compound Annual Growth Rate (CAGR) of only 1.0% between 2002 and 2011. The patent expiries of major branded products, such as Taxol (paclitaxel), Paraplatin (carboplatin), Gemzar (gemcitabine), Hycamtin (topotecan hydrochloride) and the subsequent launch of generics, have acted as restraining factors to the market. The introduction of new and promising therapies such as Avastin (bevacizumab), AMG 386, EC145, Farletuzumab (MORAb-003), Karenitecin (BNP1350), OPAXIO (paclitaxel poliglumex), OPT-821, Paclical (paclitaxel), Vargatef (BIBF 1120) and Votrient (pazopanib) are expected to drive the market from 2011–2020.
In 2011, the ovarian cancer therapeutics markets in key countries (the US, the UK, Germany, France, Italy, Spain, Japan, Brazil, Russia, India and China) were worth $736.7m collectively. The ovarian cancer therapeutics market is expected to witness three-fold growth by 2020, reaching $2,352m at a CAGR of 13.8%. This high growth rate is expected due to the strength of the pipeline candidates, which are anticipated to change the treatment paradigm of ovarian cancer when launched.
Scope- An overview of ovarian cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized global ovarian cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data by stage of the disease from 2002 to 2010, forecast for 10 years to 2020.
- Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France Japan and BRIC countries that include Brazil, Russia, India and China
- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.
- Competitor assessment including drug launch analysis and drug sales forecasts.
- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM activities, product positioning and drug sales forecast.
- Analysis of unmet need in the market and target product profile including opportunity for target product.
- Technology trends analytic framework to assess strength of pipeline.
- Pipeline analysis data providing a split by stage of the disease and line of therapy across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include microtubule stabilizers, vascular endothelial growth factor receptor (VEGFR) inhibitors, immunomodulators, folate receptor inhibitors, poly ADP ribose polymerase (PARP) inhibitors, topoisomerase inhibitors, interleukins, mammalian target of rapamycin (mTOR) inhibitors and phosphatidylinositol-3-kinase (PI3K) inhibitors.
- Clinical trials mapping of trials for ovarian cancer in different regions.
- An overview of the most promising drugs' including clinical study details, efficacy, safety, collaboration agreements, marketing rights, and launch analysis and drug sales forcasts to 2020.
- Analysis of the current and future market competition in the global ovarian cancer therapeutics market.
- Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Amgen Inc, AstraZeneca PLC, Boehringer Ingelheim GmbH, Oasmia Pharmaceutical AB, Endocyte, Inc, BioNumerik Pharmaceuticals, Inc, Eisai Inc., Cell Therapeutics, Inc, and Menarini Group,
- Analysis of licensing agreements during 2008-2010 in the ovarian cancer therapeutics market. M&A analysis which includes M&A deals by size and geography.
- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
- Direct quotes from key opinion leaders (KOL) or physicians in the ovarian cancer therapeutics market.
Reasons to buy- Develop business strategies and perform superior market quantification analysis by
- Understanding the trends shaping and driving the global ovarian cancer therapeutics market.
- Understanding treatment preferences of physicians in disease state and across treatment flow.
- Accessing market sizing, forecasts and quantified growth opportunities in the global ovarian cancer therapeutics market till 2020.
- Quantifying patient population in the global ovarian cancer market to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
- performing benchmarking analysis and growth opportunities against currently marketed products
- Identifying market entry points based on safety, efficacy, and pricing parameters.
- Assessing competitiveness of products in market by understanding the strength and weakness of current competition.
- Develop and design your in-licensing and out-licensing strategies by
- Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.
- Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.
- Track drug sales in the global ovarian cancer therapeutics market from 2002 to 2020
- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
- What's the next big thing in the global ovarian cancer therapeutics market landscape? Identify, understand and capitalize.
Keywords France Germany Italy Spain Japan Brazil Russia India China1 Table of Contents1 Table of Contents 41.1 List of Tables 81.2 List of Figures 112 Ovarian Cancer Therapeutics - Disease Overview 162.1 Overview 162.1.1 Types of Ovarian Cancer 162.2 Staging and Treatment of Ovarian Cancer 172.2.1 Stage I 212.2.2 Stage IA 212.2.3 Stage IB 212.2.4 Stage IC 212.2.5 Stage II 212.2.6 Stage IIA 212.2.7 Stage IIB 212.2.8 Stage IIC 212.2.9 Stage III 222.2.10 Stage IIIA 222.2.11 Stage IIIB 222.2.12 Stage IV 222.3 Epidemiology 222.4 Etiology 222.5 Symptoms 232.6 Risk Factors 232.7 Diagnosis 242.7.1 Physical Examination 242.7.2 Blood Tests 242.7.3 Human Chorionic Gonadotropin (hCG) Test 262.7.4 Ultrasound and CT Scans 262.7.5 Biopsy 262.8 Pathology 272.8.1 Grading 272.9 Prognosis 272.10 Treatment 282.10.1 Surgery 282.10.2 Chemotherapy 292.10.3 Radiation Therapy 292.11 Treatment Options by Stage 292.11.1 Stage IA 292.11.2 Stage IB 292.11.3 Stage IC 302.11.4 Stage IIA 302.11.5 Stage IIB, Stage IIC, Stage IIIA, Stage, IIIB, Stage IIIC, Stage IV 302.11.6 Treatment Follow-Up 302.12 Chemotherapy Regimens 322.13 GlobalData In-Depth Report Guidance 333 Ovarian Cancer Therapeutics - Market Characterization 343.1 Global 343.1.1 Market Size 343.1.2 Drivers and Restraints 423.1.3 Forecasts 453.1.4 Drug Sales 543.2 The US 563.2.1 Market Size 563.2.2 Drivers and Restraints 633.2.3 Forecasts 663.2.4 Drug Sales 733.2.5 Pricing and Reimbursements 753.3 The UK 763.3.1 Market Size 763.3.2 Drivers and Restraints 843.3.3 Forecasts 873.3.4 Drug Sales 963.3.5 Pricing and Reimbursements 983.4 Germany 993.4.1 Market Size 993.4.2 Drivers and Restraints 1073.4.3 Forecasts 1103.4.4 Drug Sales 1193.4.5 Pricing and Reimbursements 1213.5 France 1223.5.1 Market Size 1223.5.2 Drivers and Restraints 1303.5.3 Forecasts 1323.5.4 Drug Sales 1413.5.5 Pricing and Reimbursements 1433.6 Italy 1443.6.1 Market Size 1443.6.2 Drivers and Restraints 1523.6.3 Forecasts 1553.6.4 Drug Sales 1643.6.5 Pricing and Reimbursements 1663.7 Spain 1673.7.1 Market Size 1673.7.2 Drivers and Restraints 1753.7.3 Forecasts 1783.7.4 Drug Sales 1873.7.5 Pricing and Reimbursements 1893.8 Japan 1903.8.1 Market Size 1903.8.2 Drivers and Restraints 1983.8.3 Forecasts 2013.8.4 Drug Sales 2103.8.5 Pricing and Reimbursements 2123.9 Brazil 2133.9.1 Market Size 2133.9.2 Patient Volume 2163.9.3 Drivers and Restraints 2203.9.4 Impact on the Market 2223.9.5 Forecasts 2233.9.6 Future Impact 2293.10 Russia 2303.10.1 Market Size 2303.10.2 Drivers and Restraints 2363.10.3 Impact on the Market 2383.10.4 Forecasts 2393.10.5 Future Impact 2453.11 India 2463.11.1 Market Size 2463.11.2 Drivers and Restraints 2533.11.3 Impact on the Market 2553.11.4 Forecasts 2563.11.5 Future Impact 2633.12 China 2643.12.1 Market Size 2643.12.2 Drivers and Restraints 2713.12.3 Impact on the Market 2733.12.4 Forecasts 2743.12.5 Future Impact 2803.13 Key Takeaway 2804 Ovarian Cancer Therapeutics - Opportunity and Unmet Need 2814.1 Unmet Need 2814.2 First-Line Treatment of Loco-Regional and Advanced/Metastatic Setting 2824.3 Second-Line Treatment of Loco-Regional and Advanced/Metastatic Setting 2834.4 Key Takeaway 2835 Ovarian Cancer Therapeutics - Competitive Assessment 2845.1 Strategic Competitor Assessment 2845.1.1 Benchmarking 2845.1.2 Current Competitor Assessment 2925.1.3 Chemotherapy 2936 Ovarian Cancer Therapeutics - Strategic Assessment 2946.1 Key Events Impacting the Future Market 2946.2 Market Impact Analysis 2956.3 Future Market Scenario 2967 Product Profiles for the Major Marketed Products in the Ovarian Cancer Market 2977.1.1 Carboplatin 2977.1.2 Cisplatin 3047.1.3 Paclitaxel 3087.1.4 Altretamine 3147.1.5 Hycamtin (topotecan hydrochloride) 3177.1.6 Gemzar (gemcitabine) 3227.1.7 Yondelis (trabectedin) 3267.1.8 Doxil (doxorubicin Hcl liposome injection) 3317.2 Partners in Commercialization 3367.2.1 Taj Pharmaceuticals Enters Into License Agreement with AstraZeneca Pharmaceuticals for Gemcitabine HCI 3367.2.2 APP Pharmaceuticals Enters Into Licensing Agreement with Teva Pharmaceutical for Gemcitabine HCI 3367.3 Key Takeaway 3368 Ovarian Cancer - Pipeline Assessment 3378.1 Overview 3378.2 Pipeline Analysis by Phase of Development 3378.3 Pipeline by Mechanism of Action 3388.4 Pipeline by Line of Therapy 3398.5 Strategic Pipeline Assessment 3408.5.1 Technology Trends Analytic Framework 3408.6 Ovarian Cancer Pipeline – Pipeline by Clinical Phases of Development 3428.6.1 Ovarian Cancer – Pre-Registration Clinical Pipeline 3428.6.2 Ovarian Cancer – Phase III of the Clinical Pipeline 3438.6.3 Ovarian Cancer – Phase II of the Clinical Pipeline 3448.6.4 Ovarian Cancer – Phase I of the Clinical Pipeline 3488.6.5 Ovarian Cancer – Preclinical Pipeline 3508.6.6 Ovarian Cancer – Discovery Stage Pipeline 3518.7 Most Promising Drug Profiles 3518.7.1 Avastin (bevacizumab) 3518.7.2 Paclical (paclitaxel) 3548.7.3 Votrient (pazopanib) 3558.7.4 Farletuzumab (MORAb-003) 3578.7.5 Karenitecin (BNP 1350) 3598.7.6 Opaxio (xyotax, CT-2103) 3618.7.7 AMG 386 3648.7.8 EC-145 3658.7.9 Recentin (cediranib, AZD2171) 3678.7.10 Vargatef (BIBF 1120) 3688.8 Partners in Research and Development 3708.8.1 Licensing Agreements 3708.8.2 Co-development Agreements 3728.9 Key Takeaway 3759 Ovarian Cancer Therapeutics - Clinical Trials Mapping 3769.1 Clinical Trials 3769.1.1 Clinical Trials by Status 3769.1.2 Clinical Trials by Country 3779.1.3 Clinical Trials by Phase 3789.1.4 Clinical Trials by Sponsor Type 3799.1.5 Clinical Trials – Leading Sponsors 3809.1.6 Clinical Trials – Leading Company Sponsors by Phase 3819.2 Patient Recruitment 38210 Ovarian Cancer Therapeutics - Future Market Players 38310.1 F. Hoffmann-La Roche Ltd. 38310.1.1 Business Description 38310.1.2 Financial Overview 38310.1.3 SWOT Analysis 38410.2 Menarini Group 38910.2.1 Business Description 38910.2.2 Financial Overview 38910.2.3 SWOT Analysis 39010.3 GlaxoSmithKline plc. 39410.3.1 Business Description 39410.3.2 Financial Overview 39410.3.3 SWOT Analysis 39510.4 Eisai Inc., 40010.4.1 Business Description 40010.4.2 Financial Overview 40110.4.3 SWOT Analysis 40110.5 Cell Therapeutics, Inc. 40410.5.1 Business Description 40410.5.2 Financial Overview 40410.5.3 SWOT Analysis 40510.6 Amgen Inc. 40810.6.1 Business Description 40810.6.2 Financial Overview 40910.6.3 SWOT Analysis 41010.7 AstraZeneca PLC 41410.7.1 Business Description 41410.7.2 Financial Overview 41510.7.3 SWOT Analysis 41510.8 Boehringer Ingelheim GmbH 41910.8.1 Business Description 41910.8.2 Financial Overview 41910.8.3 SWOT Analysis 42010.9 Oasmia Pharmaceutical AB 42410.9.1 Business Description 42410.9.2 Financial Overview 42410.10 Endocyte, Inc. 42410.10.1 Business Description 42410.11 BioNumerik Pharmaceuticals, Inc. 42410.11.1 Business Description 42411 Ovarian Cancer Therapeutics - M&A Analysis 42511.1 Key Highlights 42511.1.1 M&A Agreements by Phase of Development 42512 Ovarian Cancer Therapeutics - Expert Opinion 42712.1 Important Data and Analysis from Key Opinion Leaders (KOLs) 42712.1.1 Treatment Options (Surgery/Chemotherapy) 42712.1.2 Treatment Options by Stage 42712.1.3 Number of Chemotherapy Cycles 42812.1.4 Future Therapies for Ovarian Cancer Treatment 42812.1.5 Future Growth Rate of the Ovarian Cancer Market 42812.1.6 Current Unmet Needs for Ovarian Cancer Treatment 42812.1.7 What Ideal Features are Required in a New Drug 42812.1.8 Past Patient Trends in Ovarian Cancer 42812.1.9 Referral Pathway 42813 Ovarian Cancer Therapeutics - Appendix 42913.1 Definitions 42913.2 Acronyms 42913.3 Research Methodology 43213.3.1 Coverage 43313.3.2 Secondary Research 43313.3.3 Forecasting 43313.3.4 Primary Research 43513.3.5 Expert Panel Validation 43613.4 Contact Us 43613.5 Disclaimer 43613.6 Sources 436
List of Tables
Table 1: Ovarian Cancer, AJCC TNM and FIGO Staging System 17Table 2: Ovarian Cancer, Classification and Treatment Protocol Stages 18Table 3: Ovarian Cancer Stages I, II & III 20Table 4: Ovarian Cancer Stage IV 21Table 5: Ovarian Cancer, Classification of Ovarian Cancer, 2011 27Table 6: Ovarian Cancer Five-Year Survival Rates 27Table 7: Ovarian Cancer Chemotherapy Regimens 32Table 8:Ovarian Cancer Therapeutics Market, Global, Sales Value ($m) by Country, 2002–2011 36Table 9: Ovarian Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2011 38Table 10: Ovarian Cancer Therapeutics Market, Global, Patient Volume, 2002–2011 40Table 11: Ovarian Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2002–2011 41Table 12: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m), 2011–2020 45Table 13: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m), 2011–2020 47Table 14: Ovarian Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2011–2020 48Table 15: Ovarian Cancer Therapeutics Market, Global, Patient Volume, 2011–2020 50Table 16: Ovarian Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2011-2020 52Table 17: Ovarian Cancer Therapeutics Market, Top Seven Countries, Drug Sales ($m), 2002–2011 54Table 18: Ovarian Cancer Therapeutics Market, Top Seven Countries, Drug Sales ($m), 2011–2020 55Table 19: Ovarian Cancer Therapeutics Market, The US, Sales Value ($m), 2002–2011 56Table 20: Ovarian Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 2002–2011 58Table 21: Ovarian Cancer Therapeutics Market, The US, Patient Volume, 2002–2011 60Table 22: Ovarian Cancer Therapeutics Market, The US, Treatment Usage Patterns, 2002–2011 61Table 23: Ovarian Cancer Therapeutics Market, The US, Sales Value ($m), 2011–2020 66Table 24: Ovarian Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 2011–2020 68Table 25: Ovarian Cancer Therapeutics Market, The US, Patient Volume, 2011–2020 70Table 26: Ovarian Cancer Therapeutics Market, The US, Treatment Usage Patterns, 2011–2020 71Table 27: Ovarian Cancer Therapeutics Market, The US, Drug Sales ($m), 2002–2011 73Table 28: Ovarian Cancer Therapeutics Market, The US, Drug Sales ($m), 2011–2020 74Table 29: Ovarian Cancer Therapeutics Market, The UK, Sales Value ($m), 2002–2011 76Table 30: Ovarian Cancer Therapeutics Market, The UK, Annual Cost of Therapy ($), 2002–2011 78Table 31: Ovarian Cancer Therapeutics Market, The UK, Patient Volume, 2002–2011 80Table 32: Ovarian Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 2002–2011 82Table 33: Ovarian Cancer Therapeutics Market, The UK, Sales Value ($m), 2011–2020 87Table 34: Ovarian Cancer Therapeutics Market, the UK, Annual Cost of Therapy ($), 2011–2020 89Table 35: Ovarian Cancer Therapeutics Market, The UK, Patient Volume, 2011–2020 91Table 36: Ovarian Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 2011–2020 93Table 37: Ovarian Cancer Therapeutics Market, The UK, Drug Sales ($m), 2002–2011 96Table 38: Ovarian Cancer Therapeutics Market, The UK, Drug Sales ($m), 2011–2020 97Table 39: Ovarian Cancer Therapeutics Market, Germany, Sales Value ($m), 2002–2011 99Table 40: Ovarian Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2002–2011 101Table 41: Ovarian Cancer Therapeutics Market, Germany, Patient Volume, 2002–2011 103Table 42: Ovarian Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 2002–2011 105Table 43: Ovarian Cancer Therapeutics Market, Germany, Sales Value ($m), 2011–2020 110Table 44: Ovarian Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2011–2020 112Table 45: Ovarian Cancer Therapeutics Market, Germany, Patient Volume, 2011–2020 114Table 46: Ovarian Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 2011–2020 116Table 47: Ovarian Cancer Therapeutics Market, Germany, Drug Sales ($m), 2002–2011 119Table 48: Ovarian Cancer Therapeutics Market, Germany, Drug Sales ($m), 2011–2020 120Table 49: Ovarian Cancer Therapeutics Market, France, Sales Value ($m), 2002–2011 122Table 50: Ovarian Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2002–2011 124Table 51: Ovarian Cancer Therapeutics Market, France, Patient Volume, 2002–2011 126Table 52: Ovarian Cancer Therapeutics Market, France, Treatment Usage Patterns, 2002–2011 128Table 53: Ovarian Cancer Therapeutics Market, France, Sales Value ($m), 2011–2020 132Table 54: Ovarian Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2011–2020 134Table 55: Ovarian Cancer Therapeutics Market, France, Patient Volume, 2011–2020 136Table 56: Ovarian Cancer Therapeutics Market, France, Treatment Usage Patterns, 2011–2020 138Table 57: Ovarian Cancer Therapeutics Market, France, Drug Sales ($m), 2002–2011 141Table 58: Ovarian Cancer Therapeutics Market, France, Drug Sales ($m), 2011–2020 142Table 59: Ovarian Cancer Therapeutics Market, Italy, Sales Value ($m), 2002–2011 144Table 60: Ovarian Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2002–2011 146Table 61: Ovarian Cancer Therapeutics Market, Italy, Patient Volume, 2002–2011 148Table 62: Ovarian Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 2002–2011 150Table 63: Ovarian Cancer Therapeutics Market, Italy, Sales Value ($m), 2011–2020 155Table 64: Ovarian Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2011–2020 157Table 65: Ovarian Cancer Therapeutics Market, Italy, Patient Volume, 2011–2020 159Table 66: Ovarian Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 2011–2020 161Table 67: Ovarian Cancer Therapeutics Market, Italy, Drug Sales ($m), 2002–2011 164Table 68: Cancer Therapeutics Market, Italy, Drug Sales ($m), 2011–2020 165Table 69: Ovarian Cancer Therapeutics Market, Spain, Sales Value ($m), 2002–2011 167Table 70: Ovarian Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2002–2011 169Table 71: Ovarian Cancer Therapeutics Market, Spain, Patient Volume, 2002–2011 171Table 72: Ovarian Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2002–2011 173Table 73: Ovarian Cancer Therapeutics Market, Spain, Sales Value ($m), 2011–2020 178Table 74: Ovarian Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2011–2020 180Table 75: Ovarian Cancer Therapeutics Market, Spain, Patient Volume, 2011–2020 182Table 76: Ovarian Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2011–2020 184Table 77: Ovarian Cancer Therapeutics Market, Spain, Drug Sales ($m), 2002–2011 187Table 78: Ovarian Cancer Therapeutics Market, Spain, Drug Sales ($m), 2011–2020 188Table 79: Ovarian Cancer Therapeutics Market, Japan, Drug Sales ($m), 2002-2011 190Table 80: Ovarian Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002–2011 192Table 81: Ovarian Cancer Therapeutics Market, Japan, Patient Volume, 2002–2011 194Table 82: Ovarian Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2002–2011 196Table 83: Ovarian Cancer Therapeutics Market, Japan, Sales Value ($m), 2011–2020 201Table 84: Ovarian Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011–2020 203Table 85: Ovarian Cancer Therapeutics Market, Japan, Patient Volume, 2011–2020 205Table 86: Ovarian Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2011–2020 207Table 87: Ovarian Cancer Therapeutics Market, Japan, Drug Sales ($m), 2002–2011 210Table 88: Ovarian Cancer Therapeutics Market, Japan, Drug Sales ($m), 2011–2020 211Table 89: Ovarian Cancer Therapeutics Market, Brazil, Sales Value ($m), 2002–2011 213Table 90: Ovarian Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2002–2011 215Table 91: Ovarian Cancer Therapeutics Market, Brazil, Patient Volume, 2002–2011 216Table 92: Ovarian Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2002–2011 218Table 93: Ovarian Cancer Therapeutics Market, Brazil, Sales Value ($m), 2011–2020 223Table 94: Ovarian Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2011–2020 225Table 95: Ovarian Cancer Therapeutics Market, Brazil, Patient Volume , 2011–2020 226Table 96: Ovarian Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2011–2020 228Table 97: Ovarian Cancer Therapeutics Market, Russia, Sales Value ($m), 2002–2011 230Table 98: Ovarian Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2002–2011 231Table 99: Ovarian Cancer Therapeutics Market, Russia, Patient Volume (Absolute), 2002–2011 232Table 100: Ovarian Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2002–2011 234Table 101: Ovarian Cancer Therapeutics Market, Russia, Sales Value ($m), 2011–2020 239Table 102: Ovarian Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2011–2020 240Table 103: Ovarian Cancer Therapeutics Market, Russia, Patient Volume (Absolute), 2011–2020 241Table 104: Ovarian Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2011–2020 243Table 105: Ovarian Cancer Therapeutics Market, India, Sales Value ($m), 2002–2011 246Table 106: Ovarian Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2002–2011 248Table 107: Ovarian Cancer Therapeutics Market, India, Patient Volume (Absolute), 2002–2011 249Table 108: Ovarian Cancer Therapeutics Market, India, Treatment Usage Patterns, 2002–2011 251Table 109: Ovarian Cancer Therapeutics Market, India, Sales Value ($m), 2011–2020 256Table 110: Ovarian Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2011–2020 258Table 111: Ovarian Cancer Therapeutics Market, India, Patient Volume (Absolute), 2011–2020 259Table 112: Ovarian Cancer Therapeutics Market, India, Treatment Usage Patterns, 2011–2020 261Table 113: Ovarian Cancer Therapeutics Market, China, Sales Value ($m), 2002–2011 264Table 114: Ovarian Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2002–2011 266Table 115: Ovarian Cancer Therapeutics Market, China, Patient Volume (Absolute), 2002–2011 267Table 116: Ovarian Cancer Therapeutics Market, China, Treatment Usage Patterns, 2002–2011 269Table 117: Ovarian Cancer Therapeutics Market, China, Sales Value ($m), 2011–2020 274Table 118: Ovarian Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2011–2020 276Table 119: Ovarian Cancer Therapeutics Market, China, Patient Volume (Absolute), 2011–2020 277Table 120: Ovarian Cancer Therapeutics Market, China, Treatment Usage Patterns, 2011–2020 279Table 121: Ovarian Cancer, Global, Clinical Endpoints – Approved Drugs, 2011 284Table 122:Ovarian Cancer, Global, Clinical Endpoints for Benchmarking, First-Line Loco-Regional and Advanced/Metastatic Setting, 2011 285Table 123: Ovarian Cancer, Global, Clinical Endpoints for Benchmarking, Second-Line Loco-Regional and Advanced/Metastatic Setting, 2011 285Table 124:Ovarian Cancer Therapeutics , Global, Safety Profile of Approved Treatment in Loco-Regional and Advanced/Metastatic Setting, 2011 292Table 125:Ovarian Cancer Therapeutics Market, Global, Carboplatin, Incidence of Adverse Effects NCIC Study, 2011 298Table 126:Ovarian Cancer Therapeutics Market, Global, Carboplatin, Incidence of Adverse Effects SWOG Study, 2011 299Table 127:Ovarian Cancer Therapeutics Market, Global, Carboplatin, Overview of Pivotal Trials, 2011 300Table 128:Ovarian Cancer Therapeutics Market, Global, Carboplatin, Progression Free Survival, 2011 301Table 129: Ovarian Cancer Therapeutics Market, Global, Carboplatin, Overall Survival, 2011 301Table 130:Ovarian Cancer Therapeutics Market, Global, Paclitaxel, Incidence of Adverse Effects in the First-Line Treatment, 2011 309Table 131:Ovarian Cancer Therapeutics Market, Global, Paclitaxel Incidence of Adverse Effects in the Second-Line Treatment, 2011 310Table 132:Ovarian Cancer Therapeutics Market, Global, Altretamine, Incidence of Adverse Effects, 2011 315Table 133:Ovarian Cancer Therapeutics, Hycamtin, Incidence of Adverse Effects, 2011 318Table 134: Ovarian Cancer Therapeutics , Gemzar, Incidence of Adverse Effects, 2011 323Table 135:Ovarian Cancer Therapeutics Market, Global, Yondelis, Incidence of Adverse Effects, 2011 327Table 136: Ovarian Cancer Therapeutics Market, Global, Doxil, Incidence of Adverse Effects, 2011 332Table 137: Ovarian Cancer, Global, Pipeline by Line of Therapy, 2011 339Table 138: Ovarian Cancer Pipeline, Pre-Registration, 2011 342Table 139: Ovarian Cancer Pipeline, Phase III, 2011 343Table 140: Ovarian Cancer Pipeline, Phase II, 2011 344Table 141: Ovarian Cancer Pipeline, Phase I, 2011 348Table 142: Ovarian Cancer Pipeline, Prelinical, 2011 350Table 143: Ovarian Cancer Pipeline, Discovery, 2011 351Table 144: Ovarian Cancer, Global, Licensing Agreements, 2009–2011 372Table 145: Ovarian Cancer, Global, Co-development Agreements, 2009–2011 374Table 146: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Status, March 2011 376Table 147: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Country, March 2011 377Table 148: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Phase, March 2011 378Table 149:Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, March 2011 379Table 150:Ovarian Cancer Therapeutics Market, Global, Clinical Trials, Leading Sponsors, March 2011 380Table 151:Ovarian Cancer Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, March 2011 381Table 152:Ovarian Cancer Therapeutics Market, Global, Clinical Trials, Average Number of Patients Recruited, March 2011 382Table 153: Ovarian Cancer, Global, M&A Deals by Geography, 2009–2011 426Table 154: Ovarian Cancer Therapeutics Market, Global, Treatment Options by Stage, 2011 427
List of Figures
Figure 1: Ovarian Cancer, Treatment Algorithm, Stage I and II 31Figure 2: Ovarian Cancer, Treatment Algorithm, Stage III and IV 31Figure 3: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m), 2002–2011 34Figure 4: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m) by Country, 2002–2011 36Figure 5: Ovarian Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2011 38Figure 6: Ovarian Cancer Therapeutics Market, Global, Patient Volume, 2002–2011 39Figure 7: Ovarian Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2002–2011 41Figure 8: Ovarian Cancer Therapeutics Market, Global, Market Drivers and Restraints, 2011 42Figure 9: Ovarian Cancer Therapeutics Market, Global, the Impact of Historical Events on the Market, 2011 44Figure 10: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m), 2011–2020 45Figure 11: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m) by Country, 2011–2020 46Figure 12: Ovarian Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2011–2020 48Figure 13: Ovarian Cancer Therapeutics Market, Global, Patient Volume, 2011–2020 50Figure 14: Ovarian Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2011–2020 52Figure 15: Ovarian Cancer Therapeutics Market, Global, Future Market Drivers and Restraints, 2011–2020 53Figure 16: Ovarian Cancer Therapeutics Market, Top Seven Countries, Drug Sales ($m), 2002-2020 54Figure 17: Ovarian Cancer Therapeutics Market, The US, Sales Value ($m), 2002–2011 56Figure 18: Ovarian Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 2002–2011 58Figure 19: Ovarian Cancer Therapeutics Market, The US, Patient Volume (absolute), 2002–2011 60Figure 20: Ovarian Cancer Therapeutics Market, The US, Treatment Usage Patterns, 2002–2011 61Figure 21: Ovarian Cancer Therapeutics Market, The US, Market Drivers and Restraints, 2011 63Figure 22: Ovarian Cancer Therapeutics Market, The US, The Impact of Historical Events on the Market, 2011 65Figure 23: Ovarian Cancer Therapeutics Market, The US, Sales Value ($m), 2011–2020 66Figure 24: Ovarian Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 2011–2020 68Figure 25: Ovarian Cancer Therapeutics Market, The US, Patient Volume (Absolute), 2011–2020 70Figure 26: Ovarian Cancer Therapeutics Market, The US, Treatment Usage Patterns, 2011–2020 71Figure 27: Ovarian Cancer Therapeutics Market, The US, Future Market Drivers and Restraints, 2011–2020 72Figure 28: Ovarian Cancer Therapeutics Market, The US, Drug Sales ($m), 2002-2020 73Figure 29: Ovarian Cancer Therapeutics Market, The UK, Sales Value ($m), 2002–2011 76Figure 30: Ovarian Cancer Therapeutics Market, The UK, Annual Cost of Therapy ($), 2002–2011 78Figure 31: Ovarian Cancer Therapeutics Market, The UK, Patient Volume (Absolute), 2002–2011 80Figure 32: Ovarian Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 2002–2011 82Figure 33: Ovarian Cancer Therapeutics Market, The UK, Market Drivers and Restraints, 2011 84Figure 34: Ovarian Cancer Therapeutics Market, The UK, The Impact of Historical Events on the Market, 2011 86Figure 35: Ovarian Cancer Therapeutics Market, The UK, Sales Value ($m), 2011–2020 87Figure 36: Ovarian Cancer Therapeutics Market, The UK, Annual Cost of Therapy ($), 2011–2020 89Figure 37: Ovarian Cancer Therapeutics Market, The UK, Patient Volume (Absolute), 2011–2020 91Figure 38: Ovarian Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 2011–2020 93Figure 39: Ovarian Cancer Therapeutics Market, The UK, Future Market Drivers and Restraints, 2011–2020 95Figure 40: Ovarian Cancer Therapeutics Market, The UK, Drug Sales ($m), 2002-2020 96Figure 41: Ovarian Cancer Therapeutics Market, Germany, Sales Value ($m), 2002–2011 99Figure 42: Ovarian Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2002–2011 101Figure 43: Ovarian Cancer Therapeutics Market, Germany, Patient Volume (Absolute), 2002–2011 103Figure 44: Ovarian Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 2002–2011 105Figure 45: Ovarian Cancer Therapeutics Market, Germany, Market Drivers and Restraints, 2011 107Figure 46: Ovarian Cancer Therapeutics Market, Germany, The Impact of Historical Events on the Market, 2011 109Figure 47: Ovarian Cancer Therapeutics Market, Germany, Sales Value ($m), 2011–2020 110Figure 48: Ovarian Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2011–2020 112Figure 49: Ovarian Cancer Therapeutics Market, Germany, Patient Volume (Absolute), 2011–2020 114Figure 50: Ovarian Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 2011–2020 116Figure 51: Ovarian Cancer Therapeutics Market, Germany, Future Market Drivers and Restraints, 2011–2020 118Figure 52: Ovarian Cancer Therapeutics Market, Germany, Drug Sales ($m), 2002-2020 119Figure 53: Ovarian Cancer Therapeutics Market, France, Sales Value ($m), 2002–2011 122Figure 54: Ovarian Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2002–2011 124Figure 55: Ovarian Cancer Therapeutics Market, France, Patient Volume (Absolute), 2002–2011 126Figure 56: Ovarian Cancer Therapeutics Market, France, Treatment Usage Patterns, 2002–2011 128Figure 57: Ovarian Cancer Therapeutics Market, France, Market Drivers and Restraints, 2011 130Figure 58: Ovarian Cancer Therapeutics Market, France, The Impact of Historical Events on the Market, 2011 131Figure 59: Ovarian Cancer Therapeutics Market, France, Sales Value ($m), 2011–2020 132Figure 60: Ovarian Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2011–2020 134Figure 61: Ovarian Cancer Therapeutics Market, France, Patient Volume (Absolute), 2011–2020 136Figure 62: Ovarian Cancer Therapeutics Market, France, Treatment Usage Patterns, 2011–2020 138Figure 63: Ovarian Cancer Therapeutics Market, France, Future Market Drivers and Restraints, 2011–2020 140Figure 64: Ovarian Cancer Therapeutics Market, France, Drug Sales ($m), 2002–2020 141Figure 65: Ovarian Cancer Therapeutics Market, Italy, Sales Value ($m), 2002–2011 144Figure 66: Ovarian Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2002–2011 146Figure 67: Ovarian Cancer Therapeutics Market, Italy, Patient Volume (Absolute), 2002–2011 148Figure 68: Ovarian Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 2002–2011 150Figure 69: Ovarian Cancer Therapeutics Market, Italy, Market Drivers and Restraints, 2011 152Figure 70: Ovarian Cancer Therapeutics Market, Italy, The Impact of Historical Events on the Market, 2011 154Figure 71: Ovarian Cancer Therapeutics Market, Italy, Sales Value ($m), 2011–2020 155Figure 72: Ovarian Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2011–2020 157Figure 73: Ovarian Cancer Therapeutics Market, Italy, Patient Volume (Absolute), 2011–2020 159Figure 74: Ovarian Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 2011–2020 161Figure 75: Ovarian Cancer Therapeutics Market, Italy, Future Market Drivers and Restraints, 2011–2020 163Figure 76: Ovarian Cancer Therapeutics Market, Italy, Drug Sales ($m), 2002-2020 164Figure 77: Ovarian Cancer Therapeutics Market, Spain, Sales Value ($m), 2002–2011 167Figure 78: Ovarian Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2002–2011 169Figure 79: Ovarian Cancer Therapeutics Market, Spain, Patient Volume (Absolute), 2002–2011 171Figure 80: Ovarian Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2002–2011 173Figure 81: Ovarian Cancer Therapeutics Market, Spain, Market Drivers and Restraints, 2011 175Figure 82: Ovarian Cancer Therapeutics Market, Spain, The Impact of Historical Events on the Market, 2011 177Figure 83: Ovarian Cancer Therapeutics Market, Spain, Sales Value ($m), 2011–2020 178Figure 84: Ovarian Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2011–2020 180Figure 85: Ovarian Cancer Therapeutics Market, Spain, Patient Volume (Absolute), 2011–2020 182Figure 86: Ovarian Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2011–2020 184Figure 87: Ovarian Cancer Therapeutics Market, Spain, Future Market Drivers and Restraints, 2011–2020 186Figure 88: Ovarian Cancer Therapeutics Market, Spain, Drug Sales ($m), 2002-2020 187Figure 89: Ovarian Cancer Therapeutics Market, Japan, Drug Sales ($m), 2002-2011 190Figure 90: Ovarian Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002–2011 192Figure 91: Ovarian Cancer Therapeutics Market, Japan, Patient Volume (Absolute), 2002–2011 194Figure 92: Ovarian Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2002–2011 196Figure 93: Ovarian Cancer Therapeutics Market, Japan, Market Drivers and Restraints, 2011 198Figure 94: Ovarian Cancer Therapeutics Market, Japan, Impact of Historical Events on the Market, 2011 200Figure 95: Ovarian Cancer Therapeutics Market, Japan, Sales Value ($m), 2011–2020 201Figure 96: Ovarian Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011–2020 203Figure 97: Ovarian Cancer Therapeutics Market, Japan, Patient Volume (Absolute), 2011–2020 205Figure 98: Ovarian Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2011–2020 207Figure 99: Ovarian Cancer Therapeutics Market, Japan, Future Market Drivers and Restraints, 2011–2020 209Figure 100: Ovarian Cancer Therapeutics Market, Japan, Drug Sales ($m), 2002-2020 210Figure 101: Ovarian Cancer Therapeutics Market, Brazil, Sales Value ($m), 2002–2011 213Figure 102: Ovarian Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2002–2011 215Figure 103: Ovarian Cancer Therapeutics Market, Brazil, Patient Volume (Absolute), 2002–2011 216Figure 104: Ovarian Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2002–2011 218Figure 105: Ovarian Cancer Therapeutics Market, Brazil, Market Drivers and Restraints, 2011 220Figure 106: Ovarian Cancer Therapeutics Market, Brazil, The Impact of Historical Events on the Market, 2011 222Figure 107: Ovarian Cancer Therapeutics Market, Brazil, Sales Value ($m), 2011–2020 223Figure 108: Ovarian Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2011–2020 225Figure 109: Ovarian Cancer Therapeutics Market, Brazil, Patient Volume (Absolute), 2011–2020 226Figure 110: Ovarian Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2011–2020 228Figure 111: Ovarian Cancer Therapeutics Market, Brazil, Future Market Drivers and Restraints, 2011–2020 229Figure 112: Ovarian Cancer Therapeutics Market, Russia, Sales Value ($m), 2002–2011 230Figure 113: Ovarian Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2002–2011 231Figure 114: Ovarian Cancer Therapeutics Market, Russia, Patient Volume (Absolute), 2002–2011 232Figure 115: Ovarian Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2002–2011 234Figure 116: Ovarian Cancer Therapeutics Market, Russia, Market Drivers and Restraints, 2011 236Figure 117: Ovarian Cance
To order this report:Therapy Industry: Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020More
Market Research ReportCheck our
Industry Analysis and InsightsNicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article